Provided by Tiger Fintech (Singapore) Pte. Ltd.

Vir Biotechnology, Inc.

8.22
+0.02000.24%
Post-market: 8.220.00000.00%18:02 EST
Volume:1.33M
Turnover:11.02M
Market Cap:1.13B
PE:-2.15
High:8.51
Open:8.26
Low:8.11
Close:8.20
Loading ...

Company Profile

Company Name:
Vir Biotechnology, Inc.
Exchange:
NASDAQ
Establishment Date:
2016
Employees:
408
Office Location:
1800 Owens Street,Suite 900,San Francisco,California,United States
Zip Code:
94158
Fax:
- -
Introduction:
Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. The company was incorporated in 2016 and is headquartered in San Francisco, California.

Directors

Name
Position
George Scangos
President, Chief Executive Officer and Director
Vicki Sato
Chairman of the Board of Director
Dipchand Nishar
Director
Klaus Frueh
Director
Kristina Burow
Director
Phillip Sharp
Director
Robert More
Director
Robert Perez
Director
Robert Taylor NELSEN
Director
Saira Ramasastry
Director

Shareholders

Name
Position
George Scangos
President, Chief Executive Officer and Director
Howard Horn
Chief Financial Officer and Secretary
Herbert Virgin
Executive Vice President, Research and Chief Scientific Officer
Jay Parrish
Chief Business Officer
Michael Kamarck
Chief Technology Officer
Phil Pang
Chief Medical Officer